https://scholars.lib.ntu.edu.tw/handle/123456789/464968
標題: | Erythropoietin produced by genetic-modified NIH/3T3 fibroblasts enhances the survival of degenerating neurons | 作者: | Li Y.-C. Chen S.-J. CHUNG-LIANG CHIEN |
公開日期: | 2015 | 出版社: | John Wiley and Sons Ltd | 卷: | 5 | 期: | 8 | 起(迄)頁: | e00356 | 來源出版物: | Brain and Behavior | 摘要: | Background: Erythropoietin (EPO) has potent neuroprotective effects. The short-term delivery of high-dose EPO seemed to improve patients' neuromuscular functions; however, excessive EPO resulted in systematically high hematocrit and thrombotic risk. In our study, we established a cellular material for future invivo studies of neurodegenerative diseases based on EPO provided regionally at a nontoxic level. Methods: A mouse EPO cDNA was subcloned into the pCMS-EGFP vector and transfected into NIH/3T3 fibroblasts to design a biological provider that can regionally release EPO for the treatment of neurological diseases. After G418 selection, a stable EPO-overexpressing cell line, EPO-3T3-EGFP, was established. To further confirm the neuroprotective abilities of secreted EPO from EPO-3T3-EGFP cells, a cell model of neurodegeneration, PC12-INT-EGFP, was applied. Results: The expression level of EPO was highly elevated in EPO-3T3-EGFP cells, and an abundant amount of EPO secreted from EPO-3T3-EGFP cells was detected in the extracellular milieu. After supplementation with conditioned medium prepared from EPO-3T3-EGFP cells, the survival rate of PC12-INT-EGFP cells was significantly enhanced. Surprisingly, a fraction of aggregated cytoskeletal EGFP-tagged α-internexin in PC12-INT-EGFP cells was disaggregated and transported into neurites dynamically. The immunocytochemical distribution of IF proteins, including NF-M, phosphorylated-NF-M, and the α-INT-EGFP fusion protein, were less aggregated in the perikaryal region and transported into neurites after the EPO treatment. Conclusion: The established EPO-overexpressing NIH/3T3 cell line, EPO-3T3-EGFP, may provide a material for future studies of cell-based therapies for neurodegenerative diseases via the secretion of EPO on a short-term, high-dose, regional basis. ? 2015 The Authors. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938741916&doi=10.1002%2fbrb3.356&partnerID=40&md5=5d60f22ea1771838049644b83d8c4a98 https://scholars.lib.ntu.edu.tw/handle/123456789/464968 |
ISSN: | 2162-3279 | DOI: | 10.1002/brb3.356 | SDG/關鍵字: | alpha internexin; complementary DNA; erythropoietin; propidium iodide; complementary DNA; erythropoietin; neuroprotective agent; recombinant protein; 3T3 cell line; animal cell; Article; cell culture; cell differentiation; cell viability; controlled study; degenerative disease; enzyme linked immunosorbent assay; fibroblast; genetic transfection; immunocytochemistry; mouse; nerve degeneration; neurologic disease; nonhuman; plasmid; priority journal; real time polymerase chain reaction; reverse transcription polymerase chain reaction; time-lapse video microscopy; Western blotting; animal; biosynthesis; genetics; human; metabolism; molecular cloning; nerve degeneration; procedures; protein engineering; Animals; Cloning, Molecular; DNA, Complementary; Erythropoietin; Humans; Mice; Nerve Degeneration; Neuroprotective Agents; NIH 3T3 Cells; Protein Engineering; Recombinant Proteins |
顯示於: | 解剖學暨細胞生物學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。